Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S6OP
|
|||
| Former ID |
DNC001941
|
|||
| Drug Name |
ISIS 110066
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Company |
Isis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nucleolin messenger RNA (NCL mRNA) | Target Info | . | [1] |
| KEGG Pathway | Pathogenic Escherichia coli infection | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Aurora B signaling | |||
| Validated targets of C-MYC transcriptional activation | ||||
| Regulation of Telomerase | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| WikiPathways | Pathogenic Escherichia coli infection | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | US patent application no. 6,165,786, Antisense modulation of nucleolin expression. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.